huMST1 Mouse
製品名
huMST1 Mouse
製品ID
C002070
系統名
C57BL/6NCya-Mst1tm1(hMST1)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huMST1 Mouse（カタログ番号C002070）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
MSP, HGFL, NF15S2, D3F15S2, DNF15S2
NCBI ID
染色体
Chr 3
MGI ID
さらに
系統詳細
MST1 (Macrophage Stimulating 1), also known as hepatocyte growth factor-like protein (HGFL), is the natural ligand for the RON receptor tyrosine kinase. MST1 serves as a critical node connecting immune regulation and metabolic homeostasis. In tumor immunology, it shapes the immune landscape of the tumor microenvironment by regulating Treg stability, dendritic cell (DC) antigen presentation, macrophage polarization, and fundamental lymphocyte functions [1-2]. In metabolic diseases, it participates in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD), diabetes, and related complications through regulation of AMPK/SREBP-1c-mediated lipid metabolism signaling, mitophagy, and YAP signaling pathways [3-5].
The huMST1 mouse model is a humanized model generated using gene-editing technology, in which the mouse Mst1 genomic region was replaced with the corresponding human MST1 genomic sequence while retaining the murine signal peptide sequence. In tumor immunology, this model can be used to evaluate the regulatory effects of MST1 on the functions of CD8+ T cells and Treg cells, and to investigate MST1-mediated immune regulatory mechanisms and its interactions with the tumor microenvironment. In metabolic diseases, this model can be utilized to explore the pathogenic mechanisms of metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, and diabetes, as well as the development of MST1-targeted therapeutics.
参考文献
Zhou J, Li L, Wu B, Feng Z, Lu Y, Wang Z. MST1/2: Important regulators of Hippo pathway in immune system associated diseases. Cancer Lett. 2024 Apr 10;587:216736.
Du X, Wen J, Wang Y, Karmaus PWF, Khatamian A, Tan H, Li Y, Guy C, Nguyen TM, Dhungana Y, Neale G, Peng J, Yu J, Chi H. Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells. Nature. 2018 Jun;558(7708):141-145.
Zhou T, Chang L, Luo Y, Zhou Y, Zhang J. Mst1 inhibition attenuates non-alcoholic fatty liver disease via reversing Parkin-related mitophagy. Redox Biol. 2019 Feb;21:101120. doi: 10.1016/j.redox.2019.101120. Epub 2019 Jan 23. Erratum in: Redox Biol. 2020 Jan;28:101299.
Wang K, Yang J, An Y, Wang J, Tan S, Xu H, Dong Y. MST1/2 regulates fibro/adipogenic progenitor fate decisions in skeletal muscle regeneration. Stem Cell Reports. 2024 Apr 9;19(4):501-514.
Wang J, Qi Z, Wu Y, Wang A, Liu Q, Zou F, Wang B, Qi S, Cao J, Hu C, Shi C, Liang Q, Wang L, Liu J, Wang W, Liu Q. Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus. Signal Transduct Target Ther. 2023 Apr 5;8(1):143.
系統作製戦略
The mouse Mst1 endogenous genomic region was replaced with the human MST1 genomic region. The murine signal peptide was preserved. The KI region may affect the expression of mouse Mir7088, while its effect on mouse Rnf123 remains unclear.
Figure 1. Gene editing strategy of huMST1 mice.
適用分野
Investigate the role of MST1 in macrophage activation, regulation of inflammatory responses, and immune cell functions;
Explore the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD), liver fibrosis, and diabetes;
Develop MST1-targeted therapeutics.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。